Literature DB >> 24429674

Autocrine and paracrine function of Angiotensin 1-7 in tissue repair during hypertension.

Weixin Meng1, Wenyuan Zhao, Tieqiang Zhao, Chang Liu, Yuanjian Chen, Hongyu Liu, Yao Sun.   

Abstract

BACKGROUND: Angiotensin-converting enzyme 2 (ACE2) cleaves angiotensin (Ang) II to generate Ang1-7, which mediates cellular actions through Mas receptors (MasR). Hypertension is accompanied by high or low circulating AngII levels and cardiac/renal injury. The purpose of this study is to explore (i) whether circulating AngII affects ACE2/MasR expressions in the hypertensive heart and kidney; and (ii) whether Ang1-7 regulates cardiac repair/remodeling responses through MasR during hypertension.
METHODS: In the first portion of the study, rats received either an AngII infusion (400ng/kg/min) for 4 weeks, leading to hypertension with high circulating AngII, or an aldosterone (ALDO, 0.75 μg/h) infusion for 4 weeks, leading to hypertension with low/normal circulating AngII. Cardiac and renal ACE2/MasR expressions were examined. We found that cardiac ACE2 was increased and MasR attenuated in both AngII and ALDO groups. However, renal ACE2 and MasR remained unchanged in both AngII- and ALDO-treated animals.
RESULTS: In the second portion, rats received AngII infusion with/without MasR antagonist (A779, 1mg/kg/day) for 4 weeks. The roles of MasR blockade in cardiac inflammation, fibrosis, apoptosis, and ventricular function were examined. Chronic AngII infusion caused scattered cardiac injuries, and A779 cotreatment exacerbated cardiac injury, resulting in aggravated inflammatory, fibrogenic, and apoptotic responses compared with the AngII group. Cardiac function, however, was unaltered in the AngII and A779 groups.
CONCLUSIONS: ACE2 and MasR expressions in the hypertensive heart and kidney are not regulated by circulating AngII levels. Ang1-7 is involved in multiple repair responses, suggesting that therapeutic strategies aimed at administering Ang1-7 hold potential for the management of cardiac remodeling.

Entities:  

Keywords:  Mas receptor blockade; angiotensin 1–7; blood pressure; heart; hypertension; kidney; repair.

Mesh:

Substances:

Year:  2014        PMID: 24429674      PMCID: PMC4017929          DOI: 10.1093/ajh/hpt270

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  40 in total

1.  Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats.

Authors:  John McMurray; Andrew P Davie
Journal:  Circulation       Date:  2002-11-12       Impact factor: 29.690

2.  Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects.

Authors:  Michikado Iwata; Randy T Cowling; Devorah Gurantz; Cristina Moore; Shen Zhang; Jason X-J Yuan; Barry H Greenberg
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-07-15       Impact factor: 4.733

3.  Chronic angiotensin-(1-7) administration improves vascular remodeling after angioplasty through the regulation of the TGF-beta/Smad signaling pathway in rabbits.

Authors:  Wutao Zeng; Weiyan Chen; Xiuyu Leng; Jian Gui He; Hong Ma
Journal:  Biochem Biophys Res Commun       Date:  2009-08-26       Impact factor: 3.575

4.  Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II.

Authors:  Koichi Yamamoto; Mitsuru Ohishi; Tomohiro Katsuya; Norihisa Ito; Masashi Ikushima; Masaharu Kaibe; Yuji Tatara; Atsushi Shiota; Sumio Sugano; Satoshi Takeda; Hiromi Rakugi; Toshio Ogihara
Journal:  Hypertension       Date:  2006-02-27       Impact factor: 10.190

5.  Angiotensin converting enzyme and myofibroblasts during tissue repair in the rat heart.

Authors:  Y Sun; K T Weber
Journal:  J Mol Cell Cardiol       Date:  1996-05       Impact factor: 5.000

6.  Angiotensin-converting enzyme 2 antagonizes angiotensin II-induced pressor response and NADPH oxidase activation in Wistar-Kyoto rats and spontaneously hypertensive rats.

Authors:  Jennifer Lo; Vaibhav B Patel; Zuocheng Wang; Jody Levasseur; Susan Kaufman; Josef M Penninger; Gavin Y Oudit
Journal:  Exp Physiol       Date:  2012-06-29       Impact factor: 2.969

Review 7.  ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis.

Authors:  A C Simões e Silva; K D Silveira; A J Ferreira; M M Teixeira
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

8.  Inhibition of angiotensin-converting enzyme and attenuation of myocardial fibrosis by lisinopril in rats receiving angiotensin II.

Authors:  Y Sun; A Ratajska; K T Weber
Journal:  J Lab Clin Med       Date:  1995-07

9.  Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology.

Authors:  Shant Der Sarkissian; Justin L Grobe; Lihui Yuan; Dhruv R Narielwala; Glenn A Walter; Michael J Katovich; Mohan K Raizada
Journal:  Hypertension       Date:  2008-02-04       Impact factor: 10.190

10.  ACE2 gene expression is up-regulated in the human failing heart.

Authors:  Andrew B Goulter; Martin J Goddard; Jennifer C Allen; Kenneth L Clark
Journal:  BMC Med       Date:  2004-05-19       Impact factor: 8.775

View more
  16 in total

1.  Molecular and Cellular Effect of Angiotensin 1-7 on Hypertensive Kidney Disease.

Authors:  Yuanjian Chen; Wenyuan Zhao; Chang Liu; Weixin Meng; Tieqiang Zhao; Syamal K Bhattacharya; Yao Sun
Journal:  Am J Hypertens       Date:  2019-04-22       Impact factor: 2.689

2.  Angiotensin-(1-7) and the Regulation of Anti-Fibrotic Signaling Pathways.

Authors:  Mark C Chappell; Ebaa M Al Zayadneh
Journal:  J Cell Signal       Date:  2017-01-27

Review 3.  The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7).

Authors:  Robson Augusto Souza Santos; Walkyria Oliveira Sampaio; Andreia C Alzamora; Daisy Motta-Santos; Natalia Alenina; Michael Bader; Maria Jose Campagnole-Santos
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

4.  Estradiol Supplement or Induced Hypertension May Attenuate the Angiotensin II Type 1 Receptor Antagonist-Promoted Renal Blood Flow Response to Graded Angiotensin II Administration in Ovariectomized Rats.

Authors:  Samira Choopani; Mehdi Nematbakhsh
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2022-07-01       Impact factor: 4.109

Review 5.  Hypotension as a marker or mediator of perioperative organ injury: a narrative review.

Authors:  Gareth L Ackland; Tom E F Abbott
Journal:  Br J Anaesth       Date:  2022-02-09       Impact factor: 11.719

Review 6.  Angiotensin-(1-7) and Alamandine on Experimental Models of Hypertension and Atherosclerosis.

Authors:  Fernando Pedro de Souza-Neto; Melissa Carvalho Santuchi; Mario de Morais E Silva; Maria José Campagnole-Santos; Rafaela Fernandes da Silva
Journal:  Curr Hypertens Rep       Date:  2018-03-14       Impact factor: 5.369

7.  Differential Regulatory Role of Soluble Klothos on Cardiac Fibrogenesis in Hypertension.

Authors:  Xue Liu; Yuanjian Chen; Cody W McCoy; Tieqiang Zhao; Darryl L Quarles; Min Pi; Syamal K Bhattacharya; Gwendalyn King; Yao Sun
Journal:  Am J Hypertens       Date:  2016-08-19       Impact factor: 2.689

8.  Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats.

Authors:  Jan Klimas; Michael Olvedy; Katarina Ochodnicka-Mackovicova; Peter Kruzliak; Sona Cacanyiova; Frantisek Kristek; Peter Krenek; Peter Ochodnicky
Journal:  J Cell Mol Med       Date:  2015-03-12       Impact factor: 5.310

9.  Angiotensin-(1-7) Attenuates Kidney Injury Due to Obstructive Nephropathy in Rats.

Authors:  Chang Seong Kim; In Jin Kim; Eun Hui Bae; Seong Kwon Ma; JongUn Lee; Soo Wan Kim
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

10.  A Murine Hypertrophic Cardiomyopathy Model: The DBA/2J Strain.

Authors:  Wenyuan Zhao; Tieqiang Zhao; Yuanjian Chen; Fengbo Zhao; Qingqing Gu; Robert W Williams; Syamal K Bhattacharya; Lu Lu; Yao Sun
Journal:  PLoS One       Date:  2015-08-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.